



Inologic Appoints Beatrice Langton-Webster as Chief Operating Officer

SEATTLE, Washington, June 1, 2005 -- Inologic, Inc. today announced the appointment of Beatrice Langton-Webster, Ph.D., as Chief Operating Officer. In this role, Dr. Langton-Webster will assume responsibility for operational aspects of the company as well as take on roles in financing and licensing efforts. She will continue to spearhead drug development efforts for late-stage discovery leads.

Dr. Langton-Webster has over 20 years experience in the biopharmaceutical industry with particular expertise in preclinical and early-stage clinical program design and management, operational management, strategic product planning and establishing strategic licensing opportunities. Prior to joining Inologic, Dr. Langton-Webster served as President and Senior Consultant for BC Associates, a consulting firm specializing in competitive and investment analysis, preclinical and clinical program design, operational and team management, and strategic planning and management. She served as Head of the Oncology Strategic Research Unit at Triton/Berlex Biosciences (Schering AG) and as Senior Director, Preclinical Development for Megabios Corporation (now Valentis Corporation). Her scientific efforts have focused on the identification of therapeutic agents that affect cell signaling. She holds a B.A. in Bacteriology from University of California, Los Angeles and a Ph.D. in medical microbiology and immunology from the University of California, Davis. She is also the inventor on a number of pivotal patents related to the erbB-2 (HER-2/neu) antibody.

"I am very excited about Inologic's drugs and pipeline. In this role I will move forward the financing and operational aspects of the company as well as continue to help mobilize the drug development efforts to advance our promising lead compounds into human clinical trials and further validate their therapeutic potential," commented Dr. Langton-Webster.

About Inologic

Inologic, Inc. is the leading biopharmaceutical company in the discovery and development of a new class of therapeutic drugs based on inositol signaling molecules and their role in regulating key cell functions. Inologic believes its proprietary compounds can affect the key signaling pathways linked to many serious diseases, including inflammation, cancer, diarrhea, and pulmonary disorders such as cystic fibrosis, and bronchitis. Inologic has a very rapid and practical approach to discovering new drug leads based on utilizing biologically relevant molecules that the cell itself uses as target scaffolds to design therapeutically effective drugs. Inologic will initially focus its development efforts on the advancement of compounds to treat cystic fibrosis and cancer.

For more information on Inologic, please visit <http://www.inologic.com> or contact Dr. Beatrice Langton-Webster, Chief Operating Officer, Inologic at (206) 448-9226.